3C
CLVS

361 Capital’s Clovis Oncology, Inc. CLVS Stock Holding History

361 Capital’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$717K Buy
+106,204
New +$804K 0.34% 151

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

361 Capital's CLVS Position: Q2 2020 in Review

361 Capital opened a new position in Clovis Oncology, Inc. (CLVS) in Q2 2020: 106,204 shares worth $717K. The stake represents 0.34% of the portfolio and ranks #151 among its holdings.

158 funds tracked by Wall St. Rank hold CLVS as of Q2 2020.

  • 361 Capital held 106,204 shares of Clovis Oncology, Inc. worth $717K as of Q2 2020.
  • Clovis Oncology, Inc. was a new 361 Capital position in Q2 2020.
  • Clovis Oncology, Inc. made up 0.34% of 361 Capital's portfolio in Q2 2020, its #151 holding.
  • 158 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2020.

Based on 361 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.